Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance

Neuro-Oncology(2023)10.1093/neuonc/noad236Source: DataRank Database

Abnormal vascular structure and function within brain metastases is linked to pembrolizumab resistance is a research paper published in Neuro-Oncology (2023). On theSindex it has a DataRank of 0.323. It has been cited 6 times, with 5 citing works in its 1-hop citation network.

N/A

0.323DataRank · unranked

Scored on demand from live citation data

Deposits data Open Access6 citations · 5 citing works in its network

Download PDF

Cite:

Linked data & code

nct

Data availability

Repositories this paper deposited data in (declared in PubMed).

ClinicalTrials.govNCT028865685

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (22 grants)Impact (FWCI 0.99)OA: greenTopics (63)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 90%Citation Network 10%

Base Score Contribution

0.292

From this paper's citation signal

Citation Network Contribution

0.0307

From 2 citing papers with measurable signal

Learn more about DataRank methodology →

Top 5 citers driving the network score

Ranked by each citer's contribution to N(p) — log1p(C_q) divided by its reference count — out of 5 citers.

Immunotherapy in lung cancer brain metastases
npj Precision Oncology202514 citations103 referencesContributes 0.026
Exosomal biomarkers and immune checkpoint inhibitors: advancements and future prospects
Cancer Cell International20257 citations211 referencesContributes 0.010
Temporal Shift When Comparing Contrast-Agent Concentration Curves Estimated Using Quantitative Susceptibility Mapping (QSM) and ΔR2*: The Association Between Vortex Parameters and Oxygen Extraction Fraction
Tomography20250 citations39 referencesContributes 0.000
Decoding the Biology of the Blood–Brain Tumor Barrier in Brain Cancer
Molecular Cancer Research20260 citations71 referencesContributes 0.000
Crosstalk in the brain tumor microenvironment: mechanisms, therapeutic strategies, and clinical advances
Military Medical Research20260 citations763 referencesContributes 0.000

Authors (43)

Kevin W Lou,Anita Giobbie‐Hurder ORCID,Ken Chang ORCID,Mishka Gidwani ORCID,Katharina Hoebel ORCID

Live enrichment

PubMed:38070147 PMC:PMC11066943 OpenAlex:https://openalex.org/W4389504849

European Union’s Horizon 2020 Programme: Marie Skłodowska-Curie

Grant: 844646-GLIOHAB

Spanish State Research Agency, Subprogram for Knowledge Generation

Grant: PID2021-127110OA-I00

National Institutes of Health

Grant: 1R21AG067562-01

Exploring the Relationship Between Tau Deposition and Neurovascular Health in Alzheimer's Disease

National Institutes of Health

Grant: 1R21GM137227-01

A Proof-of-concept of Vitamin B3 for Metabolic MR Imaging

European Union’s Horizon 2020 Programme: ERC Grant

Grant: 758657-ImPRESS

South-Eastern Norway Regional Health Authority

Grant: 2016102

South-Eastern Norway Regional Health Authority

Grant: 2017073

South-Eastern Norway Regional Health Authority

Grant: 2013069

Research Council of Norway FRIPRO

Grant: 261984

Research Council of Norway FRIPRO

Grant: 303249

Research Council of Norway FRIPRO

Grant: R01CA211238-01

Research Council of Norway FRIPRO

Grant: R01CA244975

NIGMS NIH HHS

Grant: R21 GM137227

NIBIB NIH HHS

Grant: T32 EB001680

European Research Council

Grant: 758657

American Society of Clinical Oncology Young Investigator Award

American Association for Cancer Research Breast Cancer Research Fellowship

Breast Cancer Research Foundation

Damon Runyon Cancer Research Foundation

American Brain Tumor Association

Norwegian Cancer Society

Damon Runyon Cancer Research Foundation

FWCI

0.99

Citation Percentile

0.8%

Citation Trend

2024

2025

2026

greenLicense: OUP Standard Publication Reuse

repositoryhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11066943/pdf/noad236.pdf

publisherhttps://academic.oup.com/neuro-oncology/advance-article-pdf/doi/10.1093/neuonc/noad236/56133909/noad236.pdf

publisherhttps://academic.oup.com/neuro-oncology/article-pdf/26/5/965/57393321/noad236.pdf

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/11066943

Fields of Study

Brain Metastases and TreatmentGlioma Diagnosis and TreatmentCancer Immunotherapy and Biomarkers03 medical and health sciences0302 clinical medicineHumansAntibodies, Monoclonal, HumanizedBrain NeoplasmsFemaleDrug Resistance, NeoplasmMaleMiddle AgedAgedAntineoplastic Agents, ImmunologicalMagnetic Resonance ImagingAdultPrognosisImmune Checkpoint InhibitorsNeovascularization, PathologicFollow-Up Studies

MeSH Terms

Antineoplastic Agents, ImmunologicalImmune Checkpoint InhibitorsAdultAgedBrain NeoplasmsFemaleFollow-Up StudiesHumansMagnetic Resonance ImagingMaleMiddle AgedNeovascularization, PathologicPrognosisDrug Resistance, NeoplasmAntibodies, Monoclonal, Humanized

Keywords

PembrolizumabResistance (ecology)Function (biology)MedicineInternal medicineBiologyCancerGeneticsImmunotherapyBrain metastasesFunctional ImagingCheckpoint InhibitionVascular EfficiencyMaleAdultNeovascularization, PathologicBrain NeoplasmsMiddle AgedAntibodies, Monoclonal, HumanizedPrognosisMagnetic Resonance ImagingAntineoplastic Agents, ImmunologicalDrug Resistance, NeoplasmHumansFemaleImmune Checkpoint InhibitorsAgedFollow-Up Studies

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being